Rare Blood Disorders

Rare blood disorders are a group of rare genetic disorders where the blood does not clot properly. Existing therapies for blood disorders place a high burden on patients and caregivers, requiring infusions as often as multiple times each week over a patient’s lifetime.

At Sigilon, we recognize this burden and understand that living or caring for someone with a rare blood disorder is more than just an infusion. It’s a caregiver of a young child learning to recognize the signs of a bleed or an adult having trouble with venous access or having arthritis and limited joint mobility as a result of years of infusions and peaks and troughs of factor.

Clinical Trials

Sigilon initiated a Phase 1/2 study in previously treated male patients with severe or moderately severe hemophilia A. The study is designed to evaluate the safety, tolerability, and preliminary efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors. This trial remains on clinical hold and is not actively recruiting patients.

To learn more about the study, please visit the study listing on clinicaltrials.gov or on EudraCT.

Patient Resources

North America

International

Back to Patients & Caregiver Overview